Letters, Testimony & Comments

Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the...
January 31 2014
Advancing Bioscience Industry Growth in Michigan: 2014 Best Practice Legislative Strategies To the Honorable Members of the 2014...
January 21 2014
The Honorable Rick Scott Office of the Governor State of Florida 400 S. Monroe St. Tallahassee, FL 32399-0001 Dear Governor Scott...
May 8 2013
Representative Matt Hudson Florida House of Representatives 402 South Monroe Street Tallahassee, FL 32399 Dear Representative Hudson...
February 1 2013
Biologics are complex medicines manufactured from living organisms. Unlike traditional “small molecule” drugs, biologics are...
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
January 24 2013
In December 2012, Virginia House Delegate John M. O'Bannon, III introduced the Interchangeable biosimilar biological products bill (H...
January 10 2013
February 22, 2012 Texas Health and Human Services Commission Attn: Stacey Johnston Policy Analyst Medicaid/Children’s Health...
March 1 2012
Economic Development and Jobs for the Michigan Bioscience Industry Michigan House and Senate Standings Committee on the Biosciences...
September 13 2011
Committee on Transportation New Hampshire State Senate Hearing on HB 374, banning corn-based ethanol as an additive to gasoline sold...
April 28 2011
Testimony of the Biotechnology Industry Organization (BIO) Hearing of the House Committee on Health, Education and Welfare April 13,...
April 13 2011
"An Act establishing procedures for sampling plants protected by patent or other intellectual property laws; requiring mediation of...
February 1 2011
Comments on the “Rule Requiring Use of Best Management Practices for Growing Crops to Minimize Cross Contamination” Dear...
December 14 2009
Re: Docket No. FDA-2008-D-0559, Draft Guidance for Industry on Process Validation: General Principles and Practices; Availability...
January 21 2009
January 31 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “Department”) proposed rule to amend 89 Ill. Adm. Code 140 regarding the 340B Drug Discount Program (the “Proposed Rule”).    BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products.  In Illinois BIO works in collaboration with iBIO, whose membership includes strong representation from the bio-pharmaceutical sector.  This sector accounts for a large portion of the $98 billion in biotech annual economic output and 369,000 directly and indirectly-created jobs in the state.  
January 31 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Texas Health and Human Services Commission (HHSC) proposed rule regarding 340B program reimbursement (the “Proposed Rule”).  BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. 
January 21 2014
BIO's Senior Policy Consultant, Peter Pellerito, testified before the Michigan Legislature's Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry.
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed
January 22 2014
BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
November 13 2013
The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.